Director Robert Hershberg of Adaptive Biotechnologies Corp filed a Form 4 on August 20, 2026, reporting the exercise of a stock option and the subsequent sale of common stock on August 18, 2026.

Key Highlights

  • Option exercised: Hershberg exercised a stock option for 15,000 shares of common stock at an exercise price of $6.32 per share on August 18, 2026.
  • First sale: 15,000 shares were sold at a weighted average price of $24.39, with individual transaction prices ranging from $24.38 to $24.43.
  • Second sale: 15,664 shares were sold at a weighted average price of $24.41, with individual transaction prices ranging from $24.40 to $24.44.
  • Remaining ownership: Following the transactions, Hershberg directly owns 46,683 shares of common stock.
  • Option fully consumed: The exercised option, which would have expired on October 18, 2026, was fully vested and left zero derivative securities remaining.

Hershberg's Option Exercise and Share Sales at Adaptive Biotechnologies

According to the filing, Robert Hershberg, a director at Adaptive Biotechnologies Corp (NASDAQ:ADPT), executed three transactions on August 18, 2026. The first was the exercise of a stock option covering 15,000 shares at a conversion price of $6.32 per share, coded as an "M" transaction. The filing notes that the option was fully vested and exercisable and would have expired on October 18, 2026, leaving zero derivative securities beneficially owned after the exercise.

Following the option exercise, the filing reports two separate sales of common stock on the same date. The first sale involved 15,000 shares disposed of at a weighted average price of $24.39, with individual transactions priced between $24.38 and $24.43, inclusive. The second sale covered 15,664 shares at a weighted average price of $24.41, with individual transactions priced between $24.40 and $24.44, inclusive. Both sales are coded as "S" transactions and reported as direct ownership disposals.

The filing discloses that Hershberg held 77,347 shares directly after the option exercise, then 62,347 shares after the first sale, and 46,683 shares after the second sale. The reporting person undertook to provide full per-price transaction detail to the company, any security holder, or SEC staff upon request. The Form 4 was signed on August 20, 2026, by Kyle Piskel as attorney-in-fact for Robert Hershberg.

What Was Disclosed

The filing covers a stock option exercise of 15,000 shares and two open-market sales totaling 30,664 shares by director Robert Hershberg on August 18, 2026, leaving him with 46,683 directly held shares of common stock.